SCHEMBL861503

SCHEMBL861503

O=C1NC(=O)C(=Cc2cnn3ccc(Nc4cccc(Cl)c4)nc23)S1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIM1 P11309 5/20 0.49
PIM2 Q9P1W9 3/20 0.49
HDAC4 P56524 1/20 0.44
IGF1R P08069 2/20 0.43
GSK3B P49841 1/20 0.41
PARP1 P09874 1/20 0.41
NR1H4 Q96RI1 1/20 0.40
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
TTR P02766 1/20 0.39
AKR1B1 P15121 1/20 0.39
HTT P42858 1/20 0.39
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12978877 1.00 PIM1 (0.49) PIM1PIM2HDAC4IGF1RGSK3B
SCHEMBL861502 1.00 PIM1 (0.49) PIM1PIM2HDAC4IGF1RGSK3B
SCHEMBL860273 0.91 PTP4A3 (0.45) PIM1MGAMGAASIMGAM2
SCHEMBL860272 0.91 PTP4A3 (0.45) PIM1MGAMGAASIMGAM2
SCHEMBL13073902 0.91 PTP4A3 (0.45) PIM1MGAMGAASIMGAM2
SCHEMBL860184 0.89 PIM1 (0.49) PIM1PIM2IGF1RGSK3BNR1H4
SCHEMBL860183 0.89 PIM1 (0.49) PIM1PIM2IGF1RGSK3BNR1H4
SCHEMBL12768720 0.89 PIM1 (0.49) PIM1PIM2IGF1RGSK3BNR1H4
SCHEMBL12978963 0.86 NR1H4 (0.43) PIM1PIM2HDAC4PARP1NR1H4
SCHEMBL3483094 0.86 NR1H4 (0.43) PIM1PIM2HDAC4PARP1NR1H4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367681-B2 Pyrazolopyrimidines and related heterocycles as kinase inhibitors CYLENE PHARMACEUTICALS, INC. (US) 2013-02-05 US disclosed
EP-2432473-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS Cylene Pharmaceuticals, Inc. (US) 2012-03-28 EP disclosed
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS SENHWA BIOSCIENCES, INC. (TW) 2010-12-30 US disclosed
WO-2010135581-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS CYLENE PHARMACEUTICALS, INC. (US) 2010-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331314-A1 PYRAZOLOPYRIMIDINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS PIM1, PIM2, PIM3 PIM1 1/4885PIM2 2/4885HDAC4 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.